Background Patient-reported outcome measures (PROMs) are used increasingly in clinical practice to assess patients’ quality of life (QoL). Addressing QoL is important for patients with a short life expectancy, such as those with pancreatic and
Search Results
Tara M. Mackay, Anouk E.J. Latenstein, Mirjam A.G. Sprangers, Lydia G. van der Geest, Geert-Jan Creemers, Susan van Dieren, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y.V. Homs, Evelien J.M. de Jong, I. Quintus Molenaar, Gijs A. Patijn, Lonneke V. van de Poll-Franse, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W.M. van Laarhoven, and for the Dutch Pancreatic Cancer Group
Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo
quality of life (QoL), including fatigue, pain, breathlessness, muscle weakness, and peripheral neuropathy, 11 , 12 which can negatively impact work, social, and familial roles. 13 Research has shown patients with MM experience greater symptom burden and
Romy M. van Amelsfoort, Iris Walraven, Jacobien Kieffer, Edwin P.M. Jansen, Annemieke Cats, Nicole C.T. van Grieken, Elma Meershoek-Klein Kranenbarg, Hein Putter, Johanna W. van Sandick, Karolina Sikorska, Cornelis J.H. van de Velde, Neil K. Aaronson, Marcel Verheij, and on behalf of the CRITICS Investigators
treatment strategies. 8 Assessing health-related quality of life (HRQoL) in clinical trials is increasingly important because it addresses the impact of treatment from the patient’s perspective. Recent studies by Basch et al 9 and Denis et al 10 have
Claudia S.E.W. Schuurhuizen, Patricia Marino, Annemarie M.J. Braamse, Laurien M. Buffart, Florence Joly, Karim Fizazi, Muriel Habibian, Jean-Marie Boher, Michel Soulie, Stéphane Oudard, Inge R.H.M. Konings, Henk M.W. Verheul, Joost Dekker, and Gwenaelle Gravis
(systemic) treatments may be limited, the number and extent of AEs and their impact on patient quality of life (QoL) are important. 2 Providing a representative overview of treatment-related AEs is essential for patients to make an informed decision to
Siew Tzuh Tang, Jen-Shi Chen, Fur-Hsing Wen, Wen-Chi Chou, John Wen-Cheng Chang, Chia-Hsun Hsieh, and Chen Hsiu Chen
– 9 but also may facilitate adjustment to the uncertainty inherent in EoL care decision-making, thus alleviating anxiety and depressive symptoms and improving quality of life (QoL). 10 , 11 The few randomized controlled trials (RCTs) of ACP studies
Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon, and Kristin Campbell
Background A critical aspect of breast cancer survivorship care includes addressing the negative sequelae of breast cancer therapy on health-related fitness and quality of life (QoL). The NCCN Clinical Practice Guidelines in Oncology (NCCN
Daniel Shasha, Pierre Cremieux, and Louis Harrison
. Impact of tumor hypoxia and anemia on radiation therapy outcomes . Oncologist 2002 ; 7 : 492 – 508 . 26 Demetri G Kris M Wade J , for the Procrit Study Group . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is
Elizabeth A. Rohan, Julie S. Townsend, Temeika L. Fairley, and Sherri L. Stewart
long-term care and follow-up. Clinical studies of cancer survivors have shown that comorbidities, such as obesity, and health behaviors, such as physical inactivity and heavy smoking, greatly influence overall quality of life and long-term survival of
Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel, and Joseph A. Greer
administration and reduction of both discomfort and stress of intravenous treatments. 4 Although oral therapies are perceived to offer better quality of life (QoL) compared with intravenous therapies, challenges with this treatment persist, including suboptimal
Tara M. Mackay, Lennart B. van Rijssen, Jurr O. Andriessen, Mustafa Suker, Geert-Jan Creemers, Ferry A. Eskens, Ignace H. de Hingh, Lonneke V. van de Poll-Franse, Mirjam A.G. Sprangers, Olivier R. Busch, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W. van Laarhoven, and on behalf of the Dutch Pancreatic Cancer Group
Background In line with developments toward patient-centered care, patient satisfaction is increasingly being recognized as an important outcome measure 1 and indicator of hospital quality. 2 Measuring patient satisfaction next to quality of life
